-

01:49:29 AM

LIVE Real Time AVIR Stock Market News

AVIR - Atea Pharmaceuticals Inc

03/30/21 4:01 PM

Nasdaq : AVIR

Atea Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update

Atea Pharmaceuticals, Inc.

RHEA-AI

neutral

03/23/21 7:00 AM

Nasdaq : AVIR

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on March 30, 2021

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, March 30, 2021 at 4:30 p.m. ET to report financial results for the

RHEA-AI

neutral

03/06/21 7:00 AM

Nasdaq : AVIR

Atea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic Infections

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company, today presented

RHEA-AI

neutral

02/19/21 8:30 AM

Nasdaq : AVIR

Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company, today announced

RHEA-AI

neutral

02/08/21 4:01 PM

Nasdaq : AVIR

Atea Pharmaceuticals Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company,

RHEA-AI

neutral

02/04/21 7:00 AM

Nasdaq : AVIR

Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company, today announced that the first patient has been

RHEA-AI

neutral

01/19/21 7:00 AM

Nasdaq : AVIR

Atea Pharmaceuticals Expands Senior Management Team with Key Additions in Regulatory Affairs and Investor Relations and Corporate Communications

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company, today announced that it has expanded its senior

RHEA-AI

neutral

12/21/20 7:00 AM

Nasdaq : AVIR

Atea Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections,

RHEA-AI

neutral

12/18/20 8:00 AM

Nasdaq : AVIR

Atea Pharmaceuticals Added to Russell 2000 Index

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company, today announced that it has been added to the Russell 2000 (R) Index, effective December 21, 2020, as part of the index's quarterly initial public offering (IPO)

RHEA-AI

neutral

11/25/20 7:00 AM

Nasdaq : AVIR

Atea Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections,

RHEA-AI

neutral